What's new

Powerpack

Unlock full stockrow access for only $12.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

  • Live data in your spreadsheets

    Google Sheets, Excel, the API and your AI assistant (MCP), with your own key.

See Powerpack
Screener Weekly Summary What's new Pricing

Precigen, Inc. PGEN

Healthcare  —  Biotechnology
8.54 0.33 4.02% as of 2 Oct
Market cap
$2.9B
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Precigen, Inc. (PGEN) Business Profile

Updated before January 2025

Company Overview

Precigen, Inc. (NASDAQ: PGEN) is a biotechnology company that specializes in the development of innovative gene and cell therapies. Founded in 1998 and headquartered in Germantown, Maryland, Precigen has established itself as a leader in synthetic biology and biotherapeutics. The company was originally known as Intrexon Corporation but rebranded to Precigen in 2020 to better reflect its focus on healthcare and biopharmaceutical advancements.

The company is led by Helen Sabzevari, Ph.D., who serves as the President and CEO. Dr. Sabzevari is a renowned immunologist with extensive experience in the development of immunotherapies and has been instrumental in steering Precigen toward its current strategic direction. The leadership team also includes other seasoned professionals with expertise in biotechnology, finance, and operations, ensuring a robust foundation for the company’s growth.

Core Business Segments

Precigen operates across several core business segments, focusing on cutting-edge technologies and therapies. These segments include:

1. Gene and Cell Therapy

Precigen’s primary focus is on developing next-generation gene and cell therapies to address unmet medical needs. The company leverages its proprietary UltraCAR-T® platform to create CAR-T cell therapies that are designed to be safer, more effective, and more accessible than traditional CAR-T therapies. Key products in this segment include:

  • PRGN-3005 UltraCAR-T®: A therapy targeting ovarian cancer.
  • PRGN-3006 UltraCAR-T®: Designed for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

2. Immuno-Oncology

Precigen is also advancing its portfolio in immuno-oncology, focusing on therapies that harness the immune system to fight cancer. The company’s AdenoVerse™ immunotherapy platform is a cornerstone of this segment, enabling the development of highly potent and targeted cancer treatments.

3. Synthetic Biology

The company’s synthetic biology division focuses on engineering biological systems to create novel solutions for healthcare and industrial applications. This includes the development of advanced gene circuits and other synthetic biology tools.

4. Animal Health

Precigen also has a presence in the animal health sector through its subsidiary, Exemplar Genetics. This division focuses on developing genetically engineered animal models for research and therapeutic purposes.

Business Model

Precigen’s business model is built on innovation, integration, and collaboration. The company generates revenue through a combination of:

  • Product Sales: Revenue from the commercialization of its therapies and products.
  • Collaborations and Partnerships: Precigen collaborates with pharmaceutical companies, research institutions, and other organizations to co-develop and commercialize therapies.
  • Licensing Agreements: The company licenses its proprietary technologies and platforms to third parties, generating additional revenue streams.

Precigen’s vertically integrated approach allows it to control the entire value chain, from research and development to manufacturing and commercialization. This not only ensures quality and efficiency but also enables the company to rapidly adapt to market demands.

Strategic Direction

Precigen is committed to advancing its pipeline of innovative therapies and expanding its presence in the biotechnology sector. Key strategic priorities include:

  • Pipeline Expansion: The company aims to accelerate the development of its UltraCAR-T® and AdenoVerse™ platforms, with a focus on bringing more therapies to clinical trials.
  • Global Reach: Precigen is exploring opportunities to expand its footprint in international markets, particularly in regions with high demand for advanced biotherapeutics.
  • Sustainability Goals: The company is dedicated to sustainable practices in its operations, including reducing its environmental impact and promoting ethical research practices.
  • New Product Categories: Precigen is actively exploring the potential of its synthetic biology platform to develop novel products beyond healthcare, such as bio-based industrial solutions.

Competitive Landscape

Precigen operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Kite Pharma (a Gilead Sciences company): A leader in CAR-T cell therapies.
  • Novartis: Known for its Kymriah® CAR-T therapy.
  • Bluebird Bio: Focused on gene therapies for rare diseases.
  • Moderna: A pioneer in mRNA-based therapies and vaccines.

Despite the competition, Precigen differentiates itself through its proprietary platforms, integrated business model, and focus on next-generation therapies.

Risk Factors

Like any biotechnology company, Precigen faces several risks, including:

  • Regulatory Challenges: The development and approval of new therapies are subject to stringent regulatory requirements, which can delay commercialization.
  • Market Dependence: The company’s revenue is heavily reliant on the success of its pipeline products.
  • Supply Chain Disruptions: Any disruptions in the supply chain could impact the production and delivery of therapies.
  • Competition: Intense competition in the biotechnology sector could affect market share and pricing.
  • Financial Risks: As a growth-stage company, Precigen may face challenges in securing sufficient funding for its operations and R&D activities.

Recent Developments

Precigen has made significant strides in recent years, including:

  • Clinical Trials: The company has advanced several therapies into clinical trials, including PRGN-3005 and PRGN-3006 UltraCAR-T®.
  • Partnerships: Precigen has entered into strategic collaborations to accelerate the development and commercialization of its therapies.
  • Technological Innovations: The company continues to enhance its UltraCAR-T® and AdenoVerse™ platforms, making them more efficient and scalable.
  • Global Developments: The COVID-19 pandemic highlighted the importance of biotherapeutics, creating new opportunities for companies like Precigen to address global healthcare challenges.

Investment Considerations

Strengths:

  • Proprietary platforms like UltraCAR-T® and AdenoVerse™.
  • Strong leadership team with expertise in biotechnology.
  • Robust pipeline of innovative therapies.
  • Integrated business model that ensures efficiency and quality.

Risks:

  • High dependence on pipeline success.
  • Regulatory and financial challenges.
  • Intense competition in the biotechnology sector.

Conclusion

Precigen, Inc. is well-positioned to become a leader in the biotechnology sector, thanks to its innovative platforms, robust pipeline, and strategic vision. While the company faces challenges typical of the industry, its strengths and growth potential make it an attractive option for investors seeking exposure to cutting-edge biotherapeutics. With a focus on addressing unmet medical needs and expanding its global presence, Precigen is poised for long-term success.